SynapDx Corporation, a Lexington, Mass.-based diagnostics and informatics company focused on pediatric neurodevelopmental disorders, raised $15.4m in funding.
The round was led by Google Ventures, with participation from Foundation Medical Partners and founding investors North Bridge Venture Partners and General Catalyst Partners. In conjunction with the funding, Google’s Andrew Conrad, PhD, the former chief scientific officer of LabCorp and co-founder of its National Genetics Institute, joined SynapDx’ Board of Directors.
The company intends to use the funds for the continued advancement of its test.
founded in 2010 and led by Stan Lapidus, CEO, SynapDx is currently developing a blood-based autism spectrum disorder (ASD) diagnostic test, designed to help clinicians identify children with autism earlier than they do today.
Read the company’s funding history here.